BPC-157 may enhance collagen production and fibroblast activity, which are essential for repairing damaged intestinal tissues
9.0 Patient counselling information Not to exceed the stated recommended daily dose
However, the use of experimental, non-approved peptides carries meaningful risks
We proposed that if an ACO, when entering a new agreement period, is under the 5,000-beneficiary minimum in BY1, BY2, or both, but meets this requirement in BY3, the ACO may only enter an agreement period in the BASIC track, to reduce the potential risk to the ACO and to the Shared Savings Program that we described elsewhere in the CY 2026 PFS proposed rule (90 FR 32666)
Special populations and timing considerations General timing guidelines apply to most people